Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

CNS Drugs(2021)10.1007/s40263-021-00816-xSource: DataRank Database

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status is a research paper published in CNS Drugs (2021). On theSindex it has a DataRank of 0. It has been cited 136 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access136 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 15.41)OA: greenTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Lawrence T. Park ORCID,Carlos A. Zarate ORCID,Ioline D. Henter ORCID

Live enrichment

PubMed:33904154 PMC:PMC8201267 OpenAlex:https://openalex.org/W3157093408

National Institute of Mental Health

Grant: ZIAMH002857

National Institutes of Health

Grant: 1ZIAMH002857-06

Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect

FWCI

15.41

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8201267

publisherhttps://link.springer.com/content/pdf/10.1007/s40263-021-00816-x.pdf

publisherhttps://link.springer.com/article/10.1007/s40263-021-00816-x/fulltext.html

journalhttps://doi.org/10.1007/s40263-021-00816-x

Fields of Study

Treatment of Major DepressionNeuroscience and Neuropharmacology ResearchTryptophan and brain disorders03 medical and health sciences0302 clinical medicineAnimalsAntidepressive AgentsBipolar DisorderMajor Depressive DisorderExcitatory Amino Acid AgentsGlutamic AcidHumansMood DisordersReceptors, Glutamate

MeSH Terms

AnimalsAntidepressive AgentsBipolar DisorderMajor Depressive DisorderDepressive Disorder, MajorHumansReceptors, GlutamateExcitatory Amino Acid AgentsGlutamic AcidMood Disorders

Keywords

GlutamatergicMetabotropic glutamate receptorPharmacologyNeuroscienceNMDA receptorDextromethorphanMetabotropic glutamate receptor 5Glutamate receptorMood disordersMajor depressive disorderPsychologyMedicineInternal medicinePsychiatryReceptorBipolar DisorderReceptors, GlutamateAnimalsGlutamic AcidHumansExcitatory Amino Acid AgentsAntidepressive Agents

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being